Understanding how a specific histone mutation affects brain tumor development in children
Official title: Investigating the role of dysfunctional histone H3.3 in driving early neuronal development and pediatric high-grade gliomas
Funded at University of Tx Md Anderson Can Ctr · NIH-11097333 · Data updated 2026-11-12
This study is looking at how a specific change in a gene related to brain development might lead to brain tumors in kids, with the hope that understanding this could help find better treatments for these tough-to-treat tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2021 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $301,309 |
| NIH project number | 5R01NS119493-05 |
| Project ID | NIH-11097333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are children diagnosed with high-grade gliomas, particularly those with the H3.3-G34R mutation.
✕Less likely to help
Patients with brain tumors that do not involve the H3.3-G34R mutation or those with other types of pediatric brain tumors may not benefit from this research.
What this research studies
This research investigates the role of a specific mutation in histone H3.3 and its impact on early brain development and the formation of high-grade gliomas in children. By using a genetically engineered mouse model, researchers aim to uncover the molecular mechanisms that drive these tumors, which are currently difficult to treat. The study focuses on how this mutation interacts with other genetic factors to promote tumor growth, potentially leading to new therapeutic targets. Patients may benefit from insights gained that could inform future treatment strategies for pediatric brain tumors.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for pediatric high-grade gliomas, improving outcomes for affected children.
How similar studies have gone: Previous research has shown promising results in understanding the genetic underpinnings of pediatric brain tumors, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Hu, Jian — University of Tx Md Anderson Can Ctr
- Study coordinator: Hu, Jian
Related research
Other NIH-funded projects on the same topics.
-
MT-125: a brain-penetrant treatment to slow glioblastoma spread and growth
A new drug, MT-125, taken by people with recurrent glioblastoma, targets two motor proteins to slow cancer spread and growth inside the brain.
-
How immune myeloid cells affect aggressive childhood brain tumors
Researchers are looking at whether immune cells called macrophages and neutrophils inside and around aggressive childhood brain tumors are linked to tumor behavior and survival in children with high-grade gliomas.
-
MT-125 treatment for recurrent high-grade brain tumors
Adults with recurrent high-grade gliomas will receive the brain-penetrant drug MT-125 to find safe doses and check whether it can slow tumor invasion and growth.
-
Investigating the role of immune cells in childhood brain tumors
This study is looking at how certain immune cells in the brain, called macrophages and neutrophils, affect a type of brain cancer in kids, and it hopes to find new ways to help treat these young patients better.
-
Developing mRNA therapies for a deadly pediatric brain tumor
This study is exploring a new way to treat a tough brain tumor called diffuse midline glioma in kids by using special particles to deliver gene therapy directly to the tumor, aiming to improve how we fight this disease.
-
Using oncolytic viruses to deliver genes for treating high-grade gliomas
This study is exploring a new way to treat aggressive brain tumors in kids by using special viruses that can target and destroy cancer cells, while also boosting the body's immune system to help fight the cancer better, and some patients may have the chance to try these exciting new treatments in clinical trials.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.